Operating Lease, Liability in USD of ELITE PHARMACEUTICALS INC /NV/ from Q1 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Present value of lessee's discounted obligation for lease payments from operating lease.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly Operating Lease, Liability history and change rate from Q1 2019 to Q3 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Operating Lease, Liability for the quarter ending 30 Sep 2025 was $1.8M, a 17% decline year-over-year.
Operating Lease, Liability, Quarterly (USD)
Operating Lease, Liability, YoY Quarterly Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Operating Lease, Liability (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $1.8M -$367K -17% 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 $1.91M -$356K -15.7% 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 $2.02M -$344K -14.5% 31 Mar 2025 10-K 30 Jun 2025
Q4 2024 $2.13M +$2.11M +8037% 31 Dec 2024 10-Q 13 Feb 2025
Q3 2024 $2.16M +$2.16M +99926% 30 Sep 2024 10-Q 14 Nov 2024
Q2 2024 $2.27M +$2.26M +26308% 30 Jun 2024 10-Q 14 Aug 2024
Q1 2024 $2.37M +$2.37M +109415% 31 Mar 2024 10-K 01 Jul 2024
Q4 2023 $26.2K +$5.08K +24% 31 Dec 2023 10-Q 14 Feb 2024
Q3 2023 $2.16K -$25.1K -92.1% 30 Sep 2023 10-Q 14 Nov 2023
Q2 2023 $8.59K -$981K -99.1% 30 Jun 2023 10-Q 14 Aug 2023
Q1 2023 $2.16K -$1.04M -99.8% 31 Mar 2023 10-Q 14 Nov 2023
Q4 2022 $21.1K -$1.07M -98.1% 31 Dec 2022 10-Q 14 Feb 2023
Q3 2022 $27.2K -$1.12M -97.6% 30 Sep 2022 10-Q 14 Nov 2022
Q2 2022 $990K -$220K -18.2% 30 Jun 2022 10-Q 15 Aug 2022
Q1 2022 $1.04M +$812K +358% 31 Mar 2022 10-K 29 Jun 2022
Q4 2021 $1.09M +$866K +392% 31 Dec 2021 10-Q 14 Feb 2022
Q3 2021 $1.15M +$876K +321% 30 Sep 2021 10-Q 15 Nov 2021
Q2 2021 $1.21M $0 0% 30 Jun 2021 10-Q 16 Aug 2021
Q1 2021 $227K -$148K -39.5% 31 Mar 2021 10-K 14 Jun 2021
Q4 2020 $221K -$204K -48% 31 Dec 2020 10-Q 16 Feb 2021
Q3 2020 $273K -$200K -42.2% 30 Sep 2020 10-Q 16 Nov 2020
Q2 2020 $1.21M +$689K +132% 30 Jun 2020 10-Q 16 Aug 2021
Q1 2020 $375K -$225K -37.5% 31 Mar 2020 10-K 29 Jun 2020
Q4 2019 $425K 31 Dec 2019 10-Q 10 Feb 2020
Q3 2019 $473K 30 Sep 2019 10-Q 12 Nov 2019
Q2 2019 $520K 30 Jun 2019 10-Q 09 Aug 2019
Q1 2019 $600K 02 Apr 2019 10-K 29 Jun 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.